THE BASIC AND CLINICAL STUDY OF METASTASIS IN ESOPHAGEAL CANCER--THE CORRELATION OF EXPRESSION OF ADHESION MOLECULES WITH METASTASIS--
食管癌转移的基础与临床研究--粘附分子表达与转移的相关性--
基本信息
- 批准号:06671249
- 负责人:
- 金额:$ 1.28万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for General Scientific Research (C)
- 财政年份:1994
- 资助国家:日本
- 起止时间:1994 至 1995
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
BACKGROUND : Many studies have reported the increased expression of epidermal growth factor receptor (EGFR) in various human malignancies and its association with the biologic behavior of the tumors.METHODS : We performed an immunohistochemical analysis of the EGFR in 217 cases of human esophageal squamous cell carcinoma, 161 lymph node metastases and 23 foci of squamous dysplasias.The findings were correlated with clinicopathologic features, including the clinical outcome.Southern blot analysis was performed in 42 cases for the detection of DNA amplification of the EGFR gene and subsequently was correlated with EGFR immunoreactivity.RESULTS : Epidermal growth factor receptor overexpression was detected in 71% of primary tumors and 88% of lymph node metastases, as compared to nonpathologic adjacent esophageal epithelium.Statistically significant correlations were observed between EGFR overexpression and sex, age, histologic type, and the presence of invasion.Tumor staining was classified into two patterns, homogeneous and heterogeneous, based on the distribution of EGFR-positive cells.The immunostaining patterns of primary tumors had a statistically significant correlation with histologic type, the presence of adventitial invasion, histologic stage and lymph node metastasis.There was a tendency toward a worse prognosis for those patients with EGFR overexpression in the primary tumor.Greater than 90% of the foci of squamous dysplasia demonstrated homogeneous EGFR overexpression.DNA amplification of the EGFR was observed in 21% of primary tumors, and all demonstrated immunohistochemical overexpression.CONCLUSIONS : Immunohistochemical overexpression of the EGFR,which was more frequent than EGFR DNA amplification, appears to play an important role in biologic behavior of human esophageal squamous cell carcinomas.
背景技术背景:许多研究报道表皮生长因子受体(epidermal growth factor receptor,EGFR)在多种人类恶性肿瘤中表达增高,并与肿瘤的生物学行为相关。我们对217例食管鳞癌、161例淋巴结转移癌和23例鳞状上皮不典型增生进行了EGFR免疫组化分析,并与临床病理特征进行了相关性分析,对42例患者进行Southern杂交检测EGFR基因扩增,并与EGFR免疫反应性进行相关性分析。表皮生长因子受体在71%的原发肿瘤和88%的淋巴结转移中过度表达,EGFR过表达与性别、年龄、组织学类型、根据EGFR阳性细胞的分布,肿瘤染色分为两种类型,均质型和异质型。原发性肿瘤的免疫染色类型与组织学类型,外膜浸润的存在,组织学分期和淋巴结转移。原发肿瘤中EGFR过表达的患者有预后不良的趋势。超过90%的鳞状不典型增生灶表现出均匀的EGFR过表达。在21%的原发肿瘤中观察到EGFR的DNA扩增,并且全部表现为免疫组化过表达。结论:EGFR的免疫组化过表达比EGFR DNA扩增更频繁,似乎在人食管鳞状细胞癌的生物学行为中发挥重要作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YASUHARA Hiroshi其他文献
YASUHARA Hiroshi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YASUHARA Hiroshi', 18)}}的其他基金
Risk management of surgical instrument with color code symbols
带有颜色代码符号的手术器械的风险管理
- 批准号:
22390101 - 财政年份:2010
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
An analysis of collateral formation and vascular smooth muscle cell migration
侧支形成和血管平滑肌细胞迁移的分析
- 批准号:
09671214 - 财政年份:1997
- 资助金额:
$ 1.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer
PLK1 和 EGFR 靶向纳米结构作为肺癌的单一疗法和放射增敏剂
- 批准号:
10766651 - 财政年份:2023
- 资助金额:
$ 1.28万 - 项目类别:
Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma
在 H3K27M 突变的弥漫性中线神经胶质瘤中靶向 EGFR/FOXG1 介导的 ONC201 耐药性
- 批准号:
10556344 - 财政年份:2022
- 资助金额:
$ 1.28万 - 项目类别:
Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma
在 H3K27M 突变的弥漫性中线神经胶质瘤中靶向 EGFR/FOXG1 介导的 ONC201 耐药性
- 批准号:
10337525 - 财政年份:2022
- 资助金额:
$ 1.28万 - 项目类别:
HCaRG/EGFR SIGNALING: A NOVEL MECHANISM OF REPAIR AFTER KIDNEY INJURY
HCaRG/EGFR 信号转导:肾损伤后修复的新机制
- 批准号:
334360 - 财政年份:2015
- 资助金额:
$ 1.28万 - 项目类别:
Fellowship Programs
EGFR Peptides as Vaccines in Anti-Tumor Immunity
EGFR 肽作为抗肿瘤免疫疫苗
- 批准号:
8647974 - 财政年份:2013
- 资助金额:
$ 1.28万 - 项目类别:
The Role of EGFR Negative Regulators in GI Neoplasia
EGFR 负调节因子在胃肠道肿瘤中的作用
- 批准号:
8698270 - 财政年份:2012
- 资助金额:
$ 1.28万 - 项目类别:
The Role of EGFR Negative Regulators in GI Neoplasia
EGFR 负调节因子在胃肠道肿瘤中的作用
- 批准号:
8243750 - 财政年份:2012
- 资助金额:
$ 1.28万 - 项目类别:
The Role of EGFR Negative Regulators in GI Neoplasia
EGFR 负调节因子在胃肠道肿瘤中的作用
- 批准号:
8510385 - 财政年份:2012
- 资助金额:
$ 1.28万 - 项目类别:
Role of Activated EGFR and COX-2 in Metastasis and Escape from Tumor Dormancy
激活的 EGFR 和 COX-2 在转移和逃离肿瘤休眠中的作用
- 批准号:
8301554 - 财政年份:2011
- 资助金额:
$ 1.28万 - 项目类别:
Role of Activated EGFR and COX-2 in Metastasis and Escape from Tumor Dormancy
激活的 EGFR 和 COX-2 在转移和逃离肿瘤休眠中的作用
- 批准号:
8093367 - 财政年份:2011
- 资助金额:
$ 1.28万 - 项目类别:














{{item.name}}会员




